The next chapter in cancer care: Earlier intervention and more personalized treatment are reshaping care

What’s Trending

Cancer care is entering a new phase defined by more patients and longer survivorship. More than 2.1 million Americans are expected to receive a new cancer diagnosis in 2026, with incidence rising both among younger adults and within an aging population overall.

The US cancer survivor population is projected to reach 21.6 million by 2030. Meanwhile, the 5-year relative survival rate across all cancers has reached 70% for the first time—meaning more patients are living longer with the effects of a cancer diagnosis. The result is sustained demand across the full cancer continuum, from prevention and screening through treatment, surveillance, and survivorship.

At the same time, clinical innovation is accelerating across that same continuum. Recent examples show how rapidly care is evolving:

Prevention is expanding. New research from the US, Sweden, and England suggests HPV vaccination is reducing cervical cancer incidence and mortality. Among young women who received the vaccine in England, deaths from cervical cancer before the age of 30 fell to nearly zero. Separate research found nine-valent HPV vaccination was associated with fewer HPV-related cancers among males. And ASCO research found that GLP-1 use was associated with roughly 30% lower odds of breast cancer among women who are overweight or obese. These are early signals that pharmacologic prevention may become a larger part of cancer strategy.
Screening and detection are becoming more personalized and accessible. A JAMA Network Open study found that a deep-learning risk model predicted 5-year breast cancer risk substantially better than breast density alone. At the same time, at-home HPV testing, urine-based diagnostics, and emerging multi-cancer early detection tools are moving portions of screening beyond traditional sites of care.
Treatment selection is becoming more precise. Companies such as Valar Labs are using AI and molecular data to help clinicians select individualized therapies. Other research is combining liquid biopsy, cfDNA methylation, and spatial tumor characteristics to predict which patients may respond to immunotherapy.
Breakthrough therapies are expanding treatment options. Daraxonrasib has shown promising survival results in metastatic pancreatic cancer, while bispecific antibodies, antibody-drug conjugates, mRNA vaccines, and allogeneic CAR-T continue to expand the therapeutic pipeline.
Innovation is shifting beyond new drugs to include more affordable, accessible, and operationally efficient models of cancer care. Sanofi's wearable formulation of Sarclisa can reduce administration time from hours to about 13 minutes for eligible multiple myeloma patients. Lower-dose regimens and shorter treatment models may also help programs improve affordability, preserve infusion capacity, and reduce burden on patients.

Why it Matters

The cancer care ecosystem must keep pace with rising need and accelerating innovation while maintaining financial sustainability. Cancer programs that will lead must be able to: (1) rapidly adjust their delivery models to better identify and support patients earlier in their cancer journey; (2) quickly deploy new therapies; and (3) demonstrate value in an uncertain economic environment.

Identify and support patients earlier: Rapid advances in prevention, screening, and early detection will result in more patients entering the cancer ecosystem earlier, disrupting traditional patient “funnels” and referring relationships. This will challenge health systems to establish relationships and trust in cancer care long before diagnosis. Longitudinal risk management and prevention will require health systems to provide appropriate, distributed access to emerging risk-profiling and early-detection tools. Health systems will also need to build frictionless pathways to rapidly act upon new information.
Deploy new therapies: Treatment innovation will raise the capability threshold for cancer programs. Increasingly personalized, sub-specialized, and complex therapies will place new demands on technology, space, and data capabilities. Programs will need nimble decision-making and operational models to assess and launch new therapies. Scaled, integrated programs will be better positioned to assemble the subspecialty expertise, infrastructure, and patient volumes required to keep pace.
Demonstrate value: The economics of cancer care are becoming more difficult. Expensive therapies; reimbursement pressure; site-of-care policies; and threats to 340B, Medicaid, and research funding are squeezing traditional economic models. At the same time, cancer programs will need to make bold, concentrated investments to keep advancing their care platforms and capabilities. Success will depend on delivering innovation that is coordinated, accessible, financially disciplined, and able to demonstrate value to patients and payers.

The next chapter in cancer care delivery will be driven by earlier detection, more precise treatment, and better outcomes. Sustaining a strong cancer program into the future will require pursuing these shifts across three fronts: leveraging primary care and early detection capabilities to capture patients earlier; building the clinical and operational infrastructure to rapidly deploy innovation; and structuring their oncology platforms for financial sustainability.